The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
27 Feb 2023
27 Feb 2023
Historique:
received:
14
01
2023
accepted:
13
02
2023
pubmed:
25
2
2023
medline:
25
2
2023
entrez:
24
2
2023
Statut:
aheadofprint
Résumé
Patients with cirrhosis develop complex alterations in primary hemostasis that include both hypocoagulable and hypercoagulable features. This includes thrombocytopenia, multiple alterations of platelet function, and increased plasma levels of von Willebrand factor. Contrary to the historical view that platelet dysfunction in cirrhosis might be responsible for an increased bleeding tendency, the current theory posits a rebalanced hemostasis in patients with cirrhosis. Severe thrombocytopenia is not indicative of the bleeding risk in patients undergoing invasive procedures and does not dictate per se the need for pre-procedural prophylaxis. A more comprehensive and individualized risk assessment should combine hemostatic impairment, the severity of decompensation and systemic inflammation, and the presence of additional factors that may impair platelet function, such as acute kidney injury and bacterial infections. Although there are multiple, complex alterations of platelet function in cirrhosis, their net effect is not yet fully understood. More investigations evaluating the association between alterations of platelet function and bleeding/thrombosis may improve risk stratification in patients with decompensated cirrhosis. Besides hemostasis, the assessment of von Willebrand factor Ag and ADP-induced, whole-blood platelet aggregation normalized by platelet count (VITRO score and PLT ratio) are promising biomarkers to predict the risk of hepatic decompensation and survival in both compensated and decompensated patients. Further investigations into the in vivo interplay between platelets, circulating blood elements, and endothelial cells may help advance our understanding of cirrhotic coagulopathy. Here, we review the complex changes in platelets and primary hemostasis in cirrhosis and their potential clinical implications.
Identifiants
pubmed: 36825598
doi: 10.1097/HEP.0000000000000349
pii: 01515467-990000000-00325
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.
Références
Zermatten MG, Fraga M, Moradpour D, Bertaggia Calderara D, Aliotta A, Stirnimann G, et al. Hemostatic alterations in patients with cirrhosis: from primary hemostasis to fibrinolysis. Hepatology. 2020;71:2135–48.
Ballard HS, Marcus AJ. Platelet aggregation in portal cirrhosis. Arch Intern Med. 1976;136:316–9.
Huijgens PC, Verhulst Jo C, Thijs LG. Platelet aggregation and portal cirrhosis. Arch Intern Med. 1977;137:257.
Ingeberg S, Jacobsen P, Fischer E, Bentsen KD. Platelet aggregation and release of ATP in patients with hepatic cirrhosis. Scand J Gastroenterol. 1985;20:285–8.
Laffi G, Cominelli F, Ruggiero M, Fedi S, Chiarugi VP, La Villa G, et al. Altered platelet function in cirrhosis of the liver: impairment of inositol lipid and arachidonic acid metabolism in response to agonists. Hepatology. 1988;8:1620–26.
Rubin MH, Weston MJ, Langley PG, White Y, Williams R. Platelet function in chronic liver disease: relationship to disease severity. Dig Dis Sci. 1979;24:197–202.
Thomas DP, Ream VJ, Stuart RK. Platelet aggregation in patients with Laennec’s cirrhosis of the liver. N Engl J Med. 1967;276:1344–48.
Lisman T, Caldwell SH, Burroughs AK, Northup PG, Senzolo M, Stravitz RT, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol. 2010;53:362–71.
Lisman T, Adelmeijer J, de Groot PG, Janssen HL, Leebeek FW. No evidence for an intrinsic platelet defect in patients with liver cirrhosis--studies under flow conditions. J Thromb Haemost. 2006;4:2070–72.
McRae S Physiological Haemostasis. In: Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists. In: Fitridge R, Thompson M, eds. Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists. Adelaide (AU), 2011.
Jackson SP. The growing complexity of platelet aggregation. Blood. 2007;109:5087–95.
Lowenberg EC, Meijers JC, Levi M. Platelet-vessel wall interaction in health and disease. Neth J Med. 2010;68:242–51.
Ruggeri ZM. Structure and function of von Willebrand factor. Thromb Haemost. 1999;82:576–84.
Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res. 2006;99:1293–1304.
Scridon A. Platelets and their role in hemostasis and thrombosis-from physiology to pathophysiology and therapeutic implications. Int J Mol Sci. 2022;23:12772.
Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113:340–45.
Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta. 1983;736:57–66.
Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature. 1964;202:498–99.
Whyte CS, Mitchell JL, Mutch NJ. Platelet-mediated modulation of fibrinolysis. Semin Thromb Hemost. 2017;43:115–28.
Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood. 2004;104:3943–48.
Gogstad GO, Stormorken H, Solum NO. Platelet alpha 2-antiplasmin is located in the platelet alpha-granules. Thromb Res. 1983;31:387–90.
Wan J, Konings J, de Laat B, Hackeng TM, Roest M. Added value of blood cells in thrombin generation testing. Thromb Haemost. 2021;121:1574–87.
Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med. 2004;36:707–17.
Litvinov RI, Weisel JW. Role of red blood cells in haemostasis and thrombosis. ISBT Sci Ser. 2017;12:176–83.
Weisel JW, Litvinov RI. Red blood cells: the forgotten player in hemostasis and thrombosis. J Thromb Haemost. 2019;17:271–82.
Swystun LL, Liaw PC. The role of leukocytes in thrombosis. Blood. 2016;128:753–62.
Elaskalani O, Abdol Razak NB, Metharom P. Neutrophil extracellular traps induce aggregation of washed human platelets independently of extracellular DNA and histones. Cell Commun Signal. 2018;16:24.
Ghasemzadeh M, Hosseini E. Platelet-leukocyte crosstalk: Linking proinflammatory responses to procoagulant state. Thromb Res. 2013;131:191–97.
Triplett DA. Coagulation and bleeding disorders: review and update. Clin Chem. 2000;46:1260–69.
Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. J Cardiovasc Pharmacol Ther. 2009;14:157–69.
Harle CC. Point-of-care platelet function testing. Semin Cardiothorac Vasc Anesth. 2007;11:247–51.
Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apher Sci. 2003;28:307–17.
Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990;16:1–20.
Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer--PFA-100. Semin Thromb Hemost. 1995;21(suppl 2):106–12.
Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK, et al. Platelet Physiology Subcommittee of the S. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost. 2006;4:312–19.
Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol. 2005;130:3–10.
Vazquez-Santiago M, Vilalta N, Cuevas B, Murillo J, Llobet D, Macho R, et al. Short closure time values in PFA-100(R) are related to venous thrombotic risk. Results from the RETROVE Study. Thromb Res. 2018;169:57–63.
Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962;194:927–29.
Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol. 2005;123:172–83.
Hayward CP, Pai M, Liu Y, Moffat KA, Seecharan J, Webert KE, et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost. 2009;7:676–84.
Hayes C, Kitahara S, Tcherniantchouk O. Decreased threshold of aggregation to low-dose epinephrine is evidence of platelet hyperaggregability in patients with thrombosis. Hematol Rep. 2014;6:5326.
Weber M, Gerdsen F, Gutensohn K, Schoder V, Eifrig B, Hossfeld DK. Enhanced platelet aggregation with TRAP-6 and collagen in platelet aggregometry in patients with venous thromboembolism. Thromb Res. 2002;107:325–28.
Puurunen MK, Hwang SJ, O’Donnell CJ, Tofler G, Johnson AD. Platelet function as a risk factor for venous thromboembolism in the Framingham Heart Study. Thromb Res. 2017;151:57–62.
Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96:781–88.
Manoharan A, Gemmell R, Brighton T, Dunkley S, Lopez K, Kyle P. Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Br J Haematol. 1999;105:618–25.
Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999;99:620–25.
Hartmann J, Walsh M, Grisoli A, Thomas AV, Shariff F, McCauley R, et al. Diagnosis and treatment of trauma-induced coagulopathy by viscoelastography. Semin Thromb Hemost. 2020;46:134–46.
Kujovich JL. Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program. 2015;2015:243–49.
Mallett SV, Chowdary P, Burroughs AK. Clinical utility of viscoelastic tests of coagulation in patients with liver disease. Liver Int. 2013;33:961–74.
Stravitz RT. Potential applications of thromboelastography in patients with acute and chronic liver disease. Gastroenterol Hepatol (N Y). 2012;8:513–20.
Tripodi A, Primignani M, Chantarangkul V, Viscardi Y, Dell’Era A, Fabris FM, et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res. 2009;124:132–36.
Zanetto A, Senzolo M, Vitale A, Cillo U, Radu C, Sartorello F, et al. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis. 2017;49:440–45.
Zanetto A, Senzolo M, Blasi A. Perioperative management of antithrombotic treatment. Best Pract Res Clin Anaesthesiol. 2020;34:35–50.
Craft RM, Chavez JJ, Bresee SJ, Wortham DC, Cohen E, Carroll RC. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med. 2004;143:301–9.
Navred K, Martin M, Ekdahl L, Zetterberg E, Andersson NG, Strandberg K, et al. A simplified flow cytometric method for detection of inherited platelet disorders-A comparison to the gold standard light transmission aggregometry. PLoS ONE. 2019;14:e0211130.
Michelson AD. Evaluation of platelet function by flow cytometry. Pathophysiol Haemost Thromb. 2006;35:67–82.
Rubak P, Nissen PH, Kristensen SD, Hvas AM. Investigation of platelet function and platelet disorders using flow cytometry. Platelets. 2016;27:66–74.
Podda G, Scavone M, Femia EA, Cattaneo M. Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy. Platelets. 2018;29:644–49.
Perez-Pujol S, Marker PH, Key NS. Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry A. 2007;71:38–45.
Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001;85:639–46.
Campello E, Radu CM, Zanetto A, Bulato C, Shalaby S, Spiezia L, et al. Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int. 2020;40:913–20.
Coppinger JA, Maguire PB. Insights into the platelet releasate. Curr Pharm Des. 2007;13:2640–46.
Baidildinova G, Nagy M, Jurk K, Wild PS, Ten Cate H, van der Meijden PEJ. Soluble platelet release factors as biomarkers for cardiovascular disease. Front Cardiovasc Med. 2021;8:684920.
Baaten C, Swieringa F, Misztal T, Mastenbroek TG, Feijge MAH, Bock PE, et al. Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects. Blood Adv. 2018;2:2320–31.
Eyraud D, Suner L, Dupont A, Bachelot-Loza C, Smadja DM, Helley D, et al. Evolution of platelet functions in cirrhotic patients undergoing liver transplantation: A prospective exploration over a month. PLoS ONE. 2018;13:e0200364.
Zhang R, Guo H, Xu J, Li B, Liu YJ, Cheng C, et al. Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding. Oncotarget. 2016;7:60609–22.
Zhang Y, Ramasundara SZ, Preketes-Tardiani RE, Cheng V, Lu H, Ju LA. Emerging microfluidic approaches for platelet mechanobiology and interplay with circulatory systems. Front Cardiovasc Med. 2021;8:766513.
Vinholt PJ, Frederiksen H, Hvas AM, Sprogoe U, Nielsen C. Measurement of platelet aggregation, independently of patient platelet count: a flow-cytometric approach. J Thromb Haemost. 2017;15:1191–1202.
Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116:878–85.
Moore AH. Thrombocytopenia in cirrhosis: A review of pathophysiology and management options. Clin Liver Dis (Hoboken). 2019;14:183–6.
Shalaby S, Simioni P, Campello E, Spiezia L, Gavasso S, Bizzaro D, et al. Endothelial damage of the portal vein is associated with heparin-like effect in advanced stages of cirrhosis. Thromb Haemost. 2020;120:1173–81.
Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost. 2010;8:1994–2000.
Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology. 2002;36:S57–S64.
Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest. 2013;144:1207–15.
Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol. 2009;7:689–95.
Russo FP, Zanetto A, Campello E, Bulato C, Shalaby S, Spiezia L, et al. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int. 2018;38:2210–18.
Zanetto A, Campello E, Bulato C, Gavasso S, Farinati F, Russo FP, et al. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. J Hepatol. 2022;77:660–9.
Zanetto A, Campello E, Bulato C, Gavasso S, Saggiorato G, Shalaby S, et al. Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. JHEP Rep. 2022;4:100493.
Zanetto A, Campello E, Bulato C, Gavasso S, Saggiorato G, Shalaby S, et al. More pronounced hypercoagulable state and hypofibrinolysis in patients with cirrhosis with versus without HCC. Hepatol Commun. 2021;5:1987–2000.
Zanetto A, Rinder HM, Campello E, Saggiorato G, Deng Y, Ciarleglio M, et al. Acute kidney injury in decompensated cirrhosis is associated with both hypo-coagulable and hyper-coagulable features. Hepatology. 2020;72:1327–40.
Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1437. e1421–1429.
Campello E, Zanetto A, Bulato C, Maggiolo S, Spiezia L, Russo FP, et al. Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. Liver Int. 2021;41:2455–66.
Plessier A, Denninger MH, Consigny Y, Pessione F, Francoz C, Durand F, et al. Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int. 2003;23:440–8.
Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction? J Hepatol. 2011;55:1415–27.
Ishikawa T, Ichida T, Matsuda Y, Sugitani S, Sugiyama M, Kato T, et al. Reduced expression of thrombopoietin is involved in thrombocytopenia in human and rat liver cirrhosis. J Gastroenterol Hepatol. 1998;13:907–3.
Martin TG 3rd, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med. 1997;127:285–8.
Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol. 2005;100:1311–16.
Jiang H, Li Y, Sheng Q, Dou X. Relationship between Hepatitis B virus infection and platelet production and dysfunction. Platelets. 2022;33:212–8.
Silczuk A, Habrat B. Alcohol-induced thrombocytopenia: Current review. Alcohol. 2020;86:9–16.
Lisman T, Pittau G, Leite FJ, De Boer MT, Meijer K, Kluin-Nelemans HC, et al. The circulating platelet count is not dictated by the liver, but may be determined in part by the bone marrow: analyses from human liver and stem cell transplantations. J Thromb Haemost. 2012;10:1624–30.
Schmidt KG, Rasmussen JW, Bekker C, Madsen PE. Kinetics and in vivo distribution of 111-In-labelled autologous platelets in chronic hepatic disease: mechanisms of thrombocytopenia. Scand J Haematol. 1985;34:39–46.
Aref S, Ibrahem L, El Menshawy N, Bassam A. Effect of splenectomy on platelets associated antibodies in hepatitis C patients with thrombocytopenia. Hematology. 2012;17:118–21.
Nieuwenhuijs-Moeke GJ, van den Berg TAJ, Bakker SJL, van den Heuvel MC, Struys M, Lisman T, et al. Preemptively and non-preemptively transplanted patients show a comparable hypercoagulable state prior to kidney transplantation compared to living kidney donors. PLoS ONE. 2018;13:e0200537.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol. 2022;76:1151–84.
Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73:366–413.
Roberts LN, Lisman T, Stanworth S, Hernandez-Gea V, Magnusson M, Tripodi A, et al. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. J Thromb Haemost. 2022;20:39–47.
Grabau CM, Crago SF, Hoff LK, Simon JA, Melton CA, Ott BJ, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology. 2004;40:484–8.
Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther. 2005;21:525–9.
Rowley MW, Agarwal S, Seetharam AB, Hirsch KS. Real-time ultrasound-guided paracentesis by radiologists: near zero risk of hemorrhage without correction of coagulopathy. J Vasc Interv Radiol. 2019;30:259–64.
Schepis F, Turco L, Bianchini M, Villa E. Prevention and management of bleeding risk related to invasive procedures in cirrhosis. Semin Liver Dis. 2018;38:215–29.
Cocero N, Bezzi M, Martini S, Carossa S. Oral surgical treatment of patients with chronic liver disease: assessments of bleeding and its relationship with thrombocytopenia and blood coagulation parameters. J Oral Maxillofac Surg. 2017;75:28–34.
Perdigao JP, de Almeida PC, Rocha TD, Mota MR, Soares EC, Alves AP, et al. Postoperative bleeding after dental extraction in liver pretransplant patients. J Oral Maxillofac Surg. 2012;70:e177–e184.
Zanetto A, Rinder HM, Senzolo M, Simioni P, Garcia-Tsao G. Reduced clot stability by thromboelastography as a potential indicator of procedure-related bleeding in decompensated cirrhosis. Hepatol Commun. 2021;5:272–82.
Bissonnette J, Riescher-Tuczkiewicz A, Gigante E, Bourdin C, Boudaoud L, Soliman H, et al. Predicting bleeding after liver biopsy using comprehensive clinical and laboratory investigations: a prospective analysis of 302 procedures. J Thromb Haemost. 2022;20:2786–96.
Blasi A, Machlab S, Risco R, Costa-Freixas JP, Hernandez-Cely G, Horta D, et al. A multicenter analysis of the role of prophylactic transfusion of blood products in patients with cirrhosis and esophageal varices undergoing endoscopic band ligation. JHEP Rep. 2021;3:100363.
Giannini EG, Giambruno E, Brunacci M, Plaz Torres MC, Furnari M, Bodini G, et al. Low fibrinogen levels are associated with bleeding after varices ligation in thrombocytopenic cirrhotic patients. Ann Hepatol. 2018;17:830–35.
Zanetto A, Pelizzaro F, Campello E, Bulato C, Balcar L, Gu W, et al. Severity of systemic inflammation is the main predictor of ACLF and bleeding in individuals with acutely decompensated cirrhosis. J Hepatol. 2023;77:301–311.
Soh H, Chun J, Hong SW, Park S, Lee YB, Lee HJ, et al. Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy. Gut Liver. 2020;14:755–64.
Kundumadam S, Phatharacharukul P, Reinhart K, Yousef A, Shamseddeen H, Pike F, et al. Bleeding after elective interventional endoscopic procedures in a large cohort of patients with cirrhosis. Clin Transl Gastroenterol. 2020;11:e00288.
Basili S, Raparelli V, Napoleone L, Talerico G, Corazza GR, Perticone F, et al. Platelet count does not predict bleeding in cirrhotic patients: results from the PRO-LIVER Study. Am J Gastroenterol. 2018;113:368–75.
Lisman T, Arefaine B, Adelmeijer J, Zamalloa A, Corcoran E, Smith JG, et al. Global hemostatic status in patients with acute-on-chronic liver failure and septics without underlying liver disease. J Thromb Haemost. 2021;19:85–95.
Zanetto A, Campello E, Spiezia L, Burra P, Simioni P, Senzolo M. Staging the pre-procedural prophylaxis in decompensated cirrhosis. Dig Liver Dis. 2022;54:1130–32.
Patel IJ, Rahim S, Davidson JC, Hanks SE, Tam AL, Walker TG, et al. Society of Interventional Radiology Consensus Guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions-Part II: recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol. 2019;30:1168–1184. e1161.
Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG Clinical Guideline: disorders of the hepatic and mesenteric circulation. Am J Gastroenterol. 2020;115:18–40.
Levy JH, Dutton RP, Hemphill JC 3rd, Shander A, Cooper D, Paidas MJ, et al. Multidisciplinary approach to the challenge of hemostasis. Anesth Analg. 2010;110:354–64.
Spyropoulos AC, Brohi K, Caprini J, Samama CM, Siegal D, Tafur A, et al. Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. J Thromb Haemost. 2019;17:1966–72.
Zanetto A, Northup P, Roberts L, Senzolo M. Hemostasis in cirrhosis: understanding destabilising factors during acute decompensation. J Hepatol. 2023 ;S0168-8278(23)00022-3. in press.
Alvaro D, Caporaso N, Giannini EG, Iacobellis A, Morelli M, Toniutto P, et al. Procedure-related bleeding risk in patients with cirrhosis and severe thrombocytopenia. Eur J Clin Invest. 2021;51:e13508.
Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH, Violi F, et al. Concepts and controversies in haemostasis and thrombosis associated with liver disease: proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost. 2018;118:1491–1506.
Tosetti G, Farina E, Caccia R, Sorge A, Berzuini A, Valenti L, et al. Preprocedural prophylaxis with blood products in patients with cirrhosis: Results from a survey of the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2022;54:1520–26.
Napolitano G, Iacobellis A, Merla A, Niro G, Valvano MR, Terracciano F, et al. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. Eur J Intern Med. 2017;38:79–82.
Tripodi A, Primignani M, Chantarangkul V, Lemma L, Jovani M, Rebulla P, et al. Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. Liver Int. 2013;33:362–7.
von Meijenfeldt FA, van den Boom BP, Adelmeijer J, Roberts LN, Lisman T, Bernal W. Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease. J Thromb Haemost. 2021;19:664–76.
Slichter SJ, Fitzpatrick L, Osborne B, Christoffel T, Gettinger I, Pellham E, et al. Platelets stored in whole blood at 4 degrees C: in vivo posttransfusion platelet recoveries and survivals and in vitro hemostatic function. Transfusion. 2019;59:2084–92.
Stanworth SJ, Shah A. How I use platelet transfusions. Blood. 2022;140:1925–36.
Rana R, Fernandez-Perez ER, Khan SA, Rana S, Winters JL, Lesnick TG, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion. 2006;46:1478–83.
Silliman CC, Boshkov LK, Mehdizadehkashi Z, Elzi DJ, Dickey WO, Podlosky L, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood. 2003;101:454–62.
Spiess BD. Platelet transfusions: the science behind safety, risks and appropriate applications. Best Pract Res Clin Anaesthesiol. 2010;24:65–83.
Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162:205–13.
Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med. 2007;131:702–707.
Toy P, Lowell C. TRALI--definition, mechanisms, incidence and clinical relevance. Best Pract Res Clin Anaesthesiol. 2007;21:183–193.
Peck-Radosavljevic M, Simon K, Iacobellis A, Hassanein T, Kayali Z, Tran A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). Hepatology. 2019;70:1336–48.
Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155:705–18.
Primignani M, Tosetti G, Tripodi A. Implementing pre-procedural thrombopoietin receptor agonists in cirrhotic patients with severe thrombocytopenia: Indiscriminate, selective or unneeded? Dig Liver Dis. 2021;53:1394–95.
Brown RS Jr., Imawari M, Izumi N, Osaki Y, Bentley R, Ochiai T, et al. Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag. JHEP Rep. 2021;3:100228.
Hidaka H, Kurosaki M, Tanaka H, Kudo M, Abiru S, Igura T, et al. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. Clin Gastroenterol Hepatol. 2019;17:1192–1200.
Lindquist I, Olson SR, Li A, Al-Samkari H, Jou JH, McCarty OJT, et al. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. Platelets. 2022;33:66–72.
Rose PD, Au M, Woodman RJ, Tee D, Chinnaratha MA. Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: a systematic review and meta-analysis. Dig Liver Dis. 2021;53:1396–1403.
Hirooka M, Ochi H, Hiraoka A, Koizumi Y, Tanaka T, Sunago K, et al. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease. J Gastroenterol Hepatol. 2020;35:299–304.
Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, et al. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures. PLoS ONE. 2019;14:e0211122.
Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367:716–24.
Tateishi R, Seike M, Kudo M, Tamai H, Kawazoe S, Katsube T, et al. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. J Gastroenterol. 2019;54:171–81.
Caporali C, Turco L, Prampolini F, Quaretti P, Bianchini M, Saltini D, et al. Proximal splenic artery embolization to treat refractory ascites in a patient with cirrhosis. Hepatology. 2021;74:3534–38.
Zanetto A, Barbiero G, Battistel M, Sciarrone SS, Shalaby S, Pellone M, et al. Management of portal hypertension severe complications. Minerva Gastroenterol (Torino). 2021;67:26–37.
Boyer TD, Habib S. Big spleens and hypersplenism: fix it or forget it? Liver Int. 2015;35:1492–98.
Cai M, Huang W, Lin C, Li Z, Qian J, Huang M, et al. Partial splenic embolization for thrombocytopenia in liver cirrhosis: predictive factors for platelet increment and risk factors for major complications. Eur Radiol. 2016;26:370–80.
Smith M, Ray CE. Splenic artery embolization as an adjunctive procedure for portal hypertension. Semin Intervent Radiol. 2012;29:135–39.
Zhu K, Meng X, Qian J, Huang M, Li Z, Guan S, et al. Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients. Dig Liver Dis. 2009;41:411–6.
Saab S, Brown RS Jr.. Management of thrombocytopenia in patients with chronic liver disease. Dig Dis Sci. 2019;64:2757–68.
He XH, Gu JJ, Li WT, Peng WJ, Li GD, Wang SP, et al. Comparison of total splenic artery embolization and partial splenic embolization for hypersplenism. World J Gastroenterol. 2012;18:3138–44.
Rong JJ, Liu D, Liang M, Wang QH, Sun JY, Zhang QY, et al. The impacts of different embolization techniques on splenic artery embolization for blunt splenic injury: a systematic review and meta-analysis. Mil Med Res. 2017;4:17.
Schnuriger B, Inaba K, Konstantinidis A, Lustenberger T, Chan LS, Demetriades D. Outcomes of proximal versus distal splenic artery embolization after trauma: a systematic review and meta-analysis. J Trauma. 2011;70:252–60.
Hayashi H, Beppu T, Okabe K, Masuda T, Okabe H, Baba H. Risk factors for complications after partial splenic embolization for liver cirrhosis. Br J Surg. 2008;95:744–50.
Deltenre P, Zanetto A, Saltini D, Moreno C, Schepis F. The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: Recent evolution and open questions. Hepatology. 2022;77:640–658.
Vizzutti F, Celsa C, Calvaruso V, Enea M, Battaglia S, Turco L, et al. Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: a validated prediction model. Hepatology. 2023;77:476–488.
Alvarez OA, Lopera GA, Patel V, Encarnacion CE, Palmaz JC, Lee M. Improvement of thrombocytopenia due to hypersplenism after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients. Am J Gastroenterol. 1996;91:134–37.
Lawrence SP, Lezotte DC, Durham JD, Kumpe DA, Everson GT, Bilir BM. Course of thrombocytopenia of chronic liver disease after transjugular intrahepatic portosystemic shunts (TIPS). A retrospective analysis. Dig Dis Sci. 1995;40:1575–80.
Pursnani KG, Sillin LF, Kaplan DS. Effect of transjugular intrahepatic portosystemic shunt on secondary hypersplenism. Am J Surg. 1997;173:169–73.
Gschwantler M, Vavrik J, Gebauer A, Kriwanek S, Schrutka-Kolbl C, Fleischer J, et al. Course of platelet counts in cirrhotic patients after implantation of a transjugular intrahepatic portosystemic shunt--a prospective, controlled study. J Hepatol. 1999;30:254–59.
Ansari-Gilani K, Seddigh Tonekaboni B, Nakamoto DA, Modaresi, Esfeh J. Utility of Doppler ultrasonography for predicting improvement of platelet count after transjugular intrahepatic portosystemic shunt. Gastroenterol Rep (Oxf). 2017;5:305–8.
Barney EJ, Little EC, Gerkin RD, Ramos AX, Kahn J, Wong M, et al. Coated transjugular intrahepatic portosystemic shunt does not improve thrombocytopenia in patients with liver cirrhosis. Dig Dis Sci. 2012;57:2430–37.
Jabbour N, Zajko A, Orons P, Irish W, Fung JJ, Selby RR. Does transjugular intrahepatic portosystemic shunt (TIPS) resolve thrombocytopenia associated with cirrhosis? Dig Dis Sci. 1998;43:2459–62.
Karasu Z, Gurakar A, Kerwin B, Hulagu S, Jazzar A, McFadden R, et al. Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis. Dig Dis Sci. 2000;45:1971–6.
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76:959–74.
Violi F, Leo R, Vezza E, Basili S, Cordova C, Balsano F. Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. C.A.L.C. Group. Coagulation Abnormalities in Cirrhosis Study Group. J Hepatol. 1994;20:531–6.
Blake JC, Sprengers D, Grech P, McCormick PA, McIntyre N, Burroughs AK. Bleeding time in patients with hepatic cirrhosis. BMJ. 1990;301:12–15.
Brass LF, Hoxie JA, Manning DR. Signaling through G proteins and G protein-coupled receptors during platelet activation. Thromb Haemost. 1993;70:217–23.
Laffi G, Cinotti S, Filimberti E, Ciabattoni G, Caporale R, Marra F, et al. Defective aggregation in cirrhosis is independent of in vivo platelet activation. J Hepatol. 1996;24:436–443.
Laffi G, Cominelli F, Ruggiero M, Fedi S, Chiarugi V, Gentilini P. Molecular mechanism underlying impaired platelet responsiveness in liver cirrhosis. FEBS Lett. 1987;220:217–19.
Pantaleo P, Marra F, Vizzutti F, Spadoni S, Ciabattoni G, Galli C, et al. Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis. Clin Sci (Lond). 2004;106:27–34.
Laffi G, Marra F, Failli P, Ruggiero M, Cecchi E, Carloni V, et al. Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. Gastroenterology. 1993;105:148–56.
Desai K, Mistry P, Bagget C, Burroughs AK, Bellamy MF, Owen JS. Inhibition of platelet aggregation by abnormal high density lipoprotein particles in plasma from patients with hepatic cirrhosis. Lancet. 1989;1:693–5.
Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014;18:281–91.
Noris M, Benigni A, Boccardo P, Aiello S, Gaspari F, Todeschini M, et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int. 1993;44:445–50.
Younger HM, Hadoke PW, Dillon JF, Hayes PC. Platelet function in cirrhosis and the role of humoral factors. Eur J Gastroenterol Hepatol. 1997;9:989–92.
Laffi G, Marra F, Gresele P, Romagnoli P, Palermo A, Bartolini O, et al. Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. Gastroenterology. 1992;103:641–46.
Owen JS, Hutton RA, Day RC, Bruckdorfer KR, McIntyre N. Platelet lipid composition and platelet aggregation in human liver disease. J Lipid Res. 1981;22:423–30.
Kelly DA, Tuddenham EG. Haemostatic problems in liver disease. Gut. 1986;27:339–49.
Han L, Han T, Nie C, Zhang Q, Cai J. Elevated mean platelet volume is associated with poor short-term outcomes in hepatitis B virus-related acute-on-chronic liver failure patients. Clin Res Hepatol Gastroenterol. 2015;39:331–9.
Giannini EG, Moscatelli A, Brunacci M, Zentilin P, Savarino V. Prognostic role of mean platelet volume in patients with cirrhosis. Dig Liver Dis. 2016;48:409–13.
Basili S, Raparelli V, Riggio O, Merli M, Carnevale R, Angelico F, et al. NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation. Liver Int. 2011;31:1533–40.
Egan K, Dillon A, Dunne E, Kevane B, Galvin Z, Maguire P, et al. Increased soluble GPVI levels in cirrhosis: evidence for early in vivo platelet activation. J Thromb Thrombolysis. 2017;43:54–59.
Panasiuk A, Zak J, Kasprzycka E, Janicka K, Prokopowicz D. Blood platelet and monocyte activations and relation to stages of liver cirrhosis. World J Gastroenterol. 2005;11:2754–8.
Vardareli E, Saricam T, Demirustu C, Gulbas Z. Soluble P selectin levels in chronic liver disease: relationship to disease severity. Hepatogastroenterology. 2007;54:466–9.
Ogasawara F, Fusegawa H, Haruki Y, Shiraishi K, Watanabe N, Matsuzaki S. Platelet activation in patients with alcoholic liver disease. Tokai J Exp Clin Med. 2005;30:41–48.
Sayed D, Amin NF, Galal GM. Monocyte-platelet aggregates and platelet micro-particles in patients with post-hepatitic liver cirrhosis. Thromb Res. 2010;125:e228–e233.
Alkozai EM, Porte RJ, Adelmeijer J, Zanetto A, Simioni P, Senzolo M, et al. No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. Thromb Res. 2015;135:292–7.
Potze W, Siddiqui MS, Boyett SL, Adelmeijer J, Daita K, Sanyal AJ, et al. Preserved hemostatic status in patients with non-alcoholic fatty liver disease. J Hepatol. 2016;65:980–7.
Fong JS, Kaplan BS. Impairment of platelet aggregation in hemolytic uremic syndrome: evidence for platelet “exhaustion”. Blood. 1982;60:564–70.
Luzzatto G, Fabris F, Gerunda GE, Zangrandi F, Girolami A. Failure of two anti-platelet drugs (indobufen and dipyridamole) to improve thrombocytopenia in liver cirrhosis. Acta Haematol. 1987;77:101–6.
Raparelli V, Basili S, Carnevale R, Napoleone L, Del Ben M, Nocella C, et al. Low-grade endotoxemia and platelet activation in cirrhosis. Hepatology. 2017;65:571–81.
Kunihiro N, Kawai B, Sanjo A, Osaka K, Ohnishi A. Platelet aggregation and coagulation and fibrinolysis parameters in both portal and systemic circulations in patients with cirrhosis and hepatocellular carcinoma. Hepatol Res. 2001;19:52–59.
Queck A, Carnevale R, Uschner FE, Schierwagen R, Klein S, Jansen C, et al. Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. Gut. 2020;69:1535–36.
Shalaby S, Zanetto A, Campello E, Gavasso S, Barbiero G, Battistel M, et al. Reply to “Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis”. Platelets. 2022;33:1104–6.
Anton A, Camprecios G, Perez-Campuzano V, Orts L, Garcia-Pagan JC, Hernandez-Gea V. The Pathophysiology of Portal Vein Thrombosis in Cirrhosis: Getting Deeper into Virchow’s Triad. J Clin Med. 2022;11:800.
De Candia E. Mechanisms of platelet activation by thrombin: a short history. Thromb Res. 2012;129:250–256.
Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53–61.
McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost. 2009;35:168–80.
Witters P, Freson K, Verslype C, Peerlinck K, Hoylaerts M, Nevens F, et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther. 2008;27:1017–29.
Barrison IG, Viola L, Murray-Lyon IM. Platelet prostaglandin production in alcoholic liver disease. Prostaglandins Leukot Med. 1983;10:331–44.
Hillbom M, Muuronen A, Neiman J. Liver disease and platelet function in alcoholics. Br Med J (Clin Res Ed). 1987;295:581.
Hillbom M, Neiman J. Platelet thromboxane formation capacity after ethanol withdrawal in chronic alcoholics. Haemostasis. 1988;18:170–8.
Torres Duarte AP, Dong QS, Young J, Abi-Younes S, Myers AK. Inhibition of platelet aggregation in whole blood by alcohol. Thromb Res. 1995;78:107–115.
Watanabe M, Shiraishi K, Itakura M, Matsuzaki S. Relationship between platelet membrane lipid compositions and platelet aggregability in alcoholic liver disease. Alcohol Clin Exp Res. 1998;22:97S–102S.
Panasiuk A, Prokopowicz D, Zak J, Matowicka-Karna J, Osada J, Wysocka J. Activation of blood platelets in chronic hepatitis and liver cirrhosis P-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4. Hepatogastroenterology. 2001;48:818–22.
Wang X, Jiang W, Li F, Hua F, Zhan Y, Li Y, et al. Abnormal platelet kinetics are detected before the occurrence of thrombocytopaenia in HBV-related liver disease. Liver Int. 2014;34:535–43.
Gowert NS, Klier M, Reich M, Reusswig F, Donner L, Keitel V, et al. Defective Platelet Activation and Bleeding Complications upon Cholestasis in Mice. Cell Physiol Biochem. 2017;41:2133–49.
Ben-Ari Z, Panagou M, Patch D, Bates S, Osman E, Pasi J, et al. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography. J Hepatol. 1997;26:554–9.
Pihusch R, Rank A, Gohring P, Pihusch M, Hiller E, Beuers U. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol. 2002;37:548–55.
Najafi A, Jafarian A, Makarem J, Barzin G, Salimi J, Nasiri-Toosi M, et al. Comparison of Coagulation Conditions in Patients With Liver Cirrhosis Due to Primary Sclerosing Cholangitis and Nonbiliary Causes of Cirrhosis Before Orthotopic Liver Transplant. Exp Clin Transplant. 2020;18:696–700.
Campello E, Zanetto A, Radu CM, Bulato C, Truma A, Spiezia L, et al. Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis. Dig Liver Dis. 2021;53:879–88.
Zanetto A, Campello E, Pelizzaro F, Farinati F, Burra P, Simioni P, et al. Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. Liver Int. 2022;42:1229–40.
Zanetto A, Senzolo M, Campello E, Bulato C, Gavasso S, Shalaby S, et al. Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. Cancers (Basel). 2021;13:1150.
Wang B, Zhu J, Ma X, Wang H, Qiu S, Pan B, et al. Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma. Clin Chim Acta. 2019;495:191–7.
Paternostro R, Kapzan L, Mandorfer M, Schwarzer R, Benedikt S, Viveiros A, et al. Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. J Gastroenterol Hepatol. 2020;35:1619–27.
Scheiner B, Semmler G, Maurer F, Schwabl P, Bucsics TA, Paternostro R, et al. Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. Liver Int. 2020;40:194–204.
Thachil J. Anemia--the overlooked factor in bleeding related to liver disease. J Hepatol. 2011;54:593–4; author reply 594-595.
Livio M, Gotti E, Marchesi D, Mecca G, Remuzzi G, de Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet. 1982;2:1013–15.
Homoncik M, Jilma-Stohlawetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2004;20:437–443.
Galbusera M, Remuzzi G, Boccardo P. Treatment of bleeding in dialysis patients. Semin Dial. 2009;22:279–286.
Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357:965–76.
Rahe-Meyer N, Winterhalter M, Boden A, Froemke C, Piepenbrock S, Calatzis A, et al. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol Scand. 2009;53:168–75.
Petricevic M, Biocina B, Milicic D, Konosic S, Ivancan V, Milosevic M, et al. Bleeding risk assessment using multiple electrode aggregometry in patients following coronary artery bypass surgery. J Thromb Thrombolysis. 2013;35:31–40.
Ranucci M, Pistuddi V, Di Dedda U, Menicanti L, De Vincentiis C, Baryshnikova E. Platelet function after cardiac surgery and its association with severe postoperative bleeding: the PLATFORM study. Platelets. 2019;30:908–14.
Debernardi Venon W, Ponzo P, Sacco M, Mengozzi G, Raso S, Valpreda A, et al. Usefulness of thromboelastometry in predicting the risk of bleeding in cirrhotics who undergo invasive procedures. Eur J Gastroenterol Hepatol. 2015;27:1313–19.
Balcar L, Scheiner B, Paternostro R, Simbrunner B, Jachs M, Hartl L, et al. Primary haemostasic capacity assessed by PFA-100 is not linked to decompensation/mortality or bleeding/thrombosis in patients with advanced chronic liver disease. Hepatology. 2022;76:S544–S545.
Zanetto A, Campello E, Burra P, Senzolo M, Simioni P. Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis. Liver Int. 2022;43:155–159.
Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology. 2012;56:1439–47.
La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut. 2011;60:1133–38.
Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther. 2018;47:980–88.
Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, et al. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology. 2021;73:1275–89.
Pomej K, Scheiner B, Balcar L, Nussbaumer RJ, Weinzierl J, Paternostro R, et al. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease. Dig Liver Dis. 2022;54:1376–84.
Zanetto A, Campello E, Bulato C, Burra P, Senzolo M, Simioni P. von Willebrand factor in hospitalized patients with acute decompensation of cirrhosis is increased but not associated with development of ACLF. Dig Liver Dis. 2023;44:139–141.
Burroughs AK, Matthews K, Qadiri M, Thomas N, Kernoff P, Tuddenham E, et al. Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed). 1985;291:1377–81.
Agnelli G, Parise P, Levi M, Cosmi B, Nenci GG. Effects of desmopressin on hemostasis in patients with liver cirrhosis. Haemostasis. 1995;25:241–7.
Cattaneo M, Tenconi PM, Alberca I, Garcia VV, Mannucci PM. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost. 1990;64:358–60.
Mannucci PM, Vicente V, Vianello L, Cattaneo M, Alberca I, Coccato MP, et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood. 1986;67:1148–53.
Arshad F, Stoof SC, Leebeek FW, Ruitenbeek K, Adelmeijer J, Blokzijl H, et al. Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis. Liver Int. 2015;35:1809–15.
de Franchis R, Arcidiacono PG, Carpinelli L, Andreoni B, Cestari L, Brunati S, et al. Randomized controlled trial of desmopressin plus terlipressin versus terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. Hepatology. 1993;18:1102–07.
Pivalizza EG, Warters RD, Gebhard R. Desmopressin before liver transplantation. Can J Anaesth. 2003;50:748–49.
Stanca CM, Montazem AH, Lawal A, Zhang JX, Schiano TD. Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial. J Oral Maxillofac Surg. 2010;68:138–43.
Canavese C, Salomone M, Pacitti A, Mangiarotti G, Calitri V. Reduced response of uraemic bleeding time to repeated doses of desmopressin. Lancet. 1985;1:867–68.